Patents by Inventor Barry L. Dowell

Barry L. Dowell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190315844
    Abstract: Disclosed herein are antibodies and methods of using said antibodies to detect Golgi protein 73 (GP73) and fucosylated GP73 in a sample.
    Type: Application
    Filed: April 17, 2019
    Publication date: October 17, 2019
    Inventors: Bailin Tu, Robert N. Ziemann, Bryan C. Tieman, Philip M. Hemken, Carol S. Ramsay, Carolyn J. Strobel, David J. Hawksworth, Larry G. Birkenmeyer, Cheng Zhao, Susan E. Brophy, Barry L. Dowell, Anthony S. Muerhoff
  • Patent number: 10308709
    Abstract: Disclosed herein are antibodies and methods of using said antibodies to detect Golgi protein 73 (GP73) and fucosylated GP73 in a sample.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: June 4, 2019
    Assignee: Abbott Laboratories
    Inventors: Bailin Tu, Robert N. Ziemann, Bryan C. Tieman, Philip M. Hemken, Carol S. Ramsay, Carolyn J. Strobel, David J. Hawksworth, Larry G. Birkenmeyer, Cheng Zhao, Susan E. Brophy, Barry L. Dowell, Anthony S. Muerhoff
  • Publication number: 20190004041
    Abstract: Provided herein are assays and kits useful for avoiding “prozone phenomenon” or “hook effect” and which expand the range of accurately measurable analyte concentrations.
    Type: Application
    Filed: August 8, 2018
    Publication date: January 3, 2019
    Applicant: ABBOTT LABORATORIES
    Inventors: Barry L. DOWELL, Susan GAYDA, Qiaoqiao RUAN, Joseph P. SKINNER, Sergey Y. TETIN
  • Patent number: 10073090
    Abstract: Provided herein are assays and kits useful for avoiding “prozone phenomenon” or “hook effect” and which expand the range of accurately measurable analyte concentrations.
    Type: Grant
    Filed: September 2, 2015
    Date of Patent: September 11, 2018
    Assignee: ABBOTT LABORATORIES
    Inventors: Barry L. Dowell, Susan Gayda, Qiaoqiao Ruan, Joseph P. Skinner, Sergey Y. Tetin
  • Patent number: 10067124
    Abstract: To provide a more convenient and more accurate method of assaying ProGRP by improving the stability of ProGRP which is known to be unstable in a biological sample. By using a blood sample in a condition in which a blood coagulation factor is not activated is used as a sample, the degradation of ProGRP is suppressed, whereby it is possible to store a sample for a long period of time and to improve the accuracy of an assay.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: September 4, 2018
    Assignees: Abbott Laboratories, Abbott Japan Co. Ltd.
    Inventors: Toru Yoshimura, Kenju Fujita, Barry L. Dowell
  • Publication number: 20170096477
    Abstract: Disclosed herein are antibodies and methods of using said antibodies to detect Golgi protein 73 (GP73) and fucosylated GP73 in a sample.
    Type: Application
    Filed: October 11, 2016
    Publication date: April 6, 2017
    Inventors: Bailin Tu, Robert N. Ziemann, Bryan C. Tieman, Philip M. Hemken, Carol S. Ramsay, Carolyn J. Strobel, David J. Hawksworth, Larry G. Birkenmeyer, Cheng Zhao, Susan E. Brophy, Barry L. Dowell, Anthony S. Muerhoff
  • Publication number: 20170089889
    Abstract: To provide a more convenient and more accurate method of assaying ProGRP by improving the stability of ProGRP which is known to be unstable in a biological sample. By using a blood sample in a condition in which a blood coagulation factor is not activated is used as a sample, the degradation of ProGRP is suppressed, whereby it is possible to store a sample for a long period of time and to improve the accuracy of an assay.
    Type: Application
    Filed: October 3, 2016
    Publication date: March 30, 2017
    Inventors: Toru Yoshimura, Kenju Fujita, Barry L. Dowell
  • Patent number: 9469686
    Abstract: Disclosed herein are antibodies and methods of using said antibodies to detect Golgi protein 73 (GP73) and fucosylated GP73 in a sample.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: October 18, 2016
    Assignee: ABBOTT LABORATORIES
    Inventors: Bailin Tu, Robert N. Ziemann, Bryan C. Tieman, Philip M. Hemken, Carol S. Ramsay, Carolyn J. Strobel, David J. Hawksworth, Larry G. Birkenmeyer, Cheng Zhao, Susan E. Brophy, Barry L. Dowell, Anthony S. Muerhoff
  • Patent number: 9459248
    Abstract: To provide a more convenient and more accurate method of assaying ProGRP by improving the stability of ProGRP which is known to be unstable in a biological sample. By using a blood sample in a condition in which a blood coagulation factor is not activated is used as a sample, the degradation of ProGRP is suppressed, whereby it is possible to store a sample for a long period of time and to improve the accuracy of an assay.
    Type: Grant
    Filed: June 3, 2014
    Date of Patent: October 4, 2016
    Assignees: Abbott Laboratories, Abbott Japan Co. Ltd.
    Inventors: Toru Yoshimura, Kenju Fujita, Barry L. Dowell
  • Publication number: 20160054317
    Abstract: Provided herein are assays and kits useful for avoiding “prozone phenomenon” or “hook effect” and which expand the range of accurately measurable analyte concentrations.
    Type: Application
    Filed: September 2, 2015
    Publication date: February 25, 2016
    Applicant: ABBOTT LABORATORIES
    Inventors: Barry L. DOWELL, Susan GAYDA, Qiaoqiao RUAN, Joseph P. SKINNER, Sergey Y. TETIN
  • Patent number: 9157910
    Abstract: Provided herein are assays and kits useful for avoiding “prozone phenomenon” or “hook effect” and which expand the range of accurately measurable analyte concentrations.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: October 13, 2015
    Assignee: Abbott Laboratories
    Inventors: Barry L. Dowell, Susan Gayda, Qiaoqiao Ruan, Joseph P. Skinner, Sergey Y. Tetin
  • Publication number: 20140287532
    Abstract: To provide a more convenient and more accurate method of assaying ProGRP by improving the stability of ProGRP which is known to be unstable in a biological sample. By using a blood sample in a condition in which a blood coagulation factor is not activated is used as a sample, the degradation of ProGRP is suppressed, whereby it is possible to store a sample for a long period of time and to improve the accuracy of an assay.
    Type: Application
    Filed: June 3, 2014
    Publication date: September 25, 2014
    Inventors: Toru Yoshimura, Kenju Fujita, Barry L. Dowell
  • Publication number: 20140271621
    Abstract: Disclosed herein are methods of diagnosing pancreatic cancer in a patient by detecting the presence and/or amount of at least three biomarkers of pancreatic cancer in a sample from the patient. The methods and biomarkers may be used to develop an accurate prognosis for a patient having cancer or suspected of having pancreatic cancer, or to accurately diagnose a patient having, or suspected of having pancreatic cancer. The methods and biomarkers may be used to identify and/or classify a patient as a candidate for a cancer therapy.
    Type: Application
    Filed: March 14, 2013
    Publication date: September 18, 2014
    Inventors: Philip M. Hemken, Barry L. Dowell, Gerard J. Davis
  • Publication number: 20140273035
    Abstract: Provided herein are assays and kits useful for avoiding “prozone phenomenon” or “hook effect” and which expand the range of accurately measurable analyte concentrations.
    Type: Application
    Filed: March 15, 2013
    Publication date: September 18, 2014
    Inventors: Barry L. DOWELL, Susan GAYDA, Qiaoqiao RUAN, Joseph P. SKINNER, Sergey Y. TETIN
  • Publication number: 20140271453
    Abstract: Provided are methods of diagnosing lung cancer, particularly at an early stage, such as stage I, by detecting the presence and/or amount of at least four biomarkers of lung cancer in a sample from a subject as well as determining the number of smoking pack years for the subject. The methods and biomarkers may be used to develop an accurate prognosis for a patient having lung cancer or suspected of having lung cancer or accurately diagnose a subject having or suspected of having lung cancer. The methods and biomarkers may be used to identify and/or classify a patient as a candidate for lung cancer treatment therapy.
    Type: Application
    Filed: March 14, 2013
    Publication date: September 18, 2014
    Inventors: Barry L. Dowell, Philip M. Hemken
  • Patent number: 8748108
    Abstract: Disclosed are methods for classifying a patient with cancer as a candidate for therapy with a Bcl-2 family inhibitor comprising determining the level of at least one biomarker in a sample and comparing the biomarker level to a threshold level. Also described are methods for identifying classes of patients having a refractory cancer for second-line therapy comprising a Bcl-2 family inhibitor, where the method comprises determining the level of at least one biomarker in a sample and comparing the biomarker level to a threshold level.
    Type: Grant
    Filed: December 6, 2011
    Date of Patent: June 10, 2014
    Assignee: AbbVie Inc.
    Inventors: Evelyn M. McKeegan, Barry L. Dowell, Richard R. Lesniewski, Dimitrí Semizarov
  • Publication number: 20130217145
    Abstract: The present invention relates to antibodies or binding proteins which bind to PIVKA II and may be used, for example, in the diagnosis, treatment and prevention of hepatocellular carcinoma (HCC), liver cancer and related conditions.
    Type: Application
    Filed: September 6, 2012
    Publication date: August 22, 2013
    Applicant: ABBOTT LABORATORIES
    Inventors: Toru Yoshimura, Sharmila Manoj, Bailin Tu, Barry L. Dowell, Gangamani Beligere, Qiaoqiao Ruan, Anthony S. Muehoff
  • Patent number: 8283162
    Abstract: The present invention relates to antibodies that may be used, for example, in the diagnosis, treatment and prevention of haepatocellular carcinoma (HCC), liver cancer and related conditions.
    Type: Grant
    Filed: March 10, 2009
    Date of Patent: October 9, 2012
    Assignee: Abbott Laboratories
    Inventors: Toru Yoshimura, Barry L. Dowell, Gangamani S. Beligere, Qiaoqiao Ruan
  • Publication number: 20120190563
    Abstract: Methods and kits for predicting the sensitivity of a cancer to treatment with a targeted tyrosine kinase inhibitor are disclosed.
    Type: Application
    Filed: May 4, 2011
    Publication date: July 26, 2012
    Applicant: ABBOTT LABORATORIES
    Inventors: Evelyn M. McKeegan, Peter Ansell, Barry L. Dowell, Ke Zhang, Viswanath Devanarayan
  • Publication number: 20120178632
    Abstract: Disclosed are methods for classifying a patient with cancer as a candidate for therapy with a Bcl-2 family inhibitor comprising determining the level of at least one biomarker in a sample and comparing the biomarker level to a threshold level. Also described are methods for identifying classes of patients having a refractory cancer for second-line therapy comprising a Bcl-2 family inhibitor, where the method comprises determining the level of at least one biomarker in a sample and comparing the biomarker level to a threshold level.
    Type: Application
    Filed: December 6, 2011
    Publication date: July 12, 2012
    Inventors: EVELYN M. MCKEEGAN, BARRY L. DOWELL, RICHARD R. LESNIEWSKI, DIMITRI SEMIZAROV